-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 12, 2021, Immune-Onc Therapeutics announced that the US FDA has approved the IND application for IO-108, which is a potential for targeting leukocyte immunoglobulin-like receptor B2 (LILRB2, also known as ILT4) The "first-in-class" new antibody is used to treat solid tumors
IO-108 can bind to LILRB2 with high affinity and specificity to block the interaction of LILRB2 with a variety of ligands involved in cancer-related immunosuppression
Pre-clinical studies have shown that as a single-agent treatment, IO-108 can reverse the anti-inflammatory bone marrow cell phenotype and promote the differentiation of monocytes into pro-inflammatory dendritic cells
▲Operation mechanism of IO-108 (picture source: Immune-Onc official website)
The multi-center, dose-escalating phase 1 clinical trial will include a single-agent cohort and a combination therapy cohort, and will evaluate the safety of IO-108 as a single-agent treatment and the combination of anti-PD-1 therapy Keytruda (pembrolizumab).
Dr.
Reference materials:
[1] Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate First-In-Human Trial of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Advanced Solid Tumors.